Alamar Biosciences (NASDAQ:ALMR) Shares Gap Down on Insider Selling

Key Points

• Alamar shares opened sharply lower, falling from a prior close of $30.22 to $28.02 after major shareholder Qiming sold shares in multiple October and November transactions, substantially reducing its position.
• The company reported a third-quarter loss of $0.19 per share, narrower than analysts’ expected $0.22 loss, and revenue of $33.55 million; it also raised its 2026 revenue guidance.
• Analysts’ average rating is Hold, with a consensus price target of $31.80. Alamar also announced research collaborations with GSK and Nightingale Health.

Alamar Biosciences, Inc. (NASDAQ:ALMR - Get Free Report)'s stock price gapped down before the market opened on Wednesday after an insider sold shares in the company. The stock had previously closed at $30.22, but opened at $28.02. Alamar Biosciences shares last traded at $27.89, with a volume of 117,911 shares trading hands.

Specifically, major shareholder Corporate Gp Vi Ltd. Qiming sold 43,930 shares of the business's stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $29.84, for a total transaction of $1,310,871.20. Following the transaction, the insider owned 160,913 shares of the company's stock, valued at approximately $4,801,643.92. The trade was a 21.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Corporate Gp Vi Ltd. Qiming sold 143,706 shares of the stock in a transaction on Friday, October 30th. The shares were sold at an average price of $30.38, for a total value of $4,365,788.28. Following the sale, the insider owned 161,679 shares in the company, valued at $4,911,808.02. The trade was a 47.06% decrease in their position. The disclosure for this sale is available in the SEC filing. In related news, major shareholder Corporate Gp Vi Ltd. Qiming sold 100,837 shares of the firm's stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $32.77, for a total value of $3,304,428.49. Following the completion of the sale, the insider directly owned 164,191 shares in the company, valued at $5,380,539.07. This trade represents a 38.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Weiss Ratings cut shares of Alamar Biosciences from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, October 23rd. TD Cowen restated a "buy" rating on shares of Alamar Biosciences in a report on Wednesday, July 15th. JPMorgan Chase & Co. lifted their price target on shares of Alamar Biosciences from $32.00 to $35.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 11th. Finally, Stifel Nicolaus upped their price target on shares of Alamar Biosciences from $28.00 to $32.00 and gave the company a "buy" rating in a report on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Alamar Biosciences has an average rating of "Hold" and a consensus target price of $31.80.

Key Alamar Biosciences News

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: Alamar reported a third-quarter loss of $0.19 per share, narrower than analysts’ expected $0.22 loss, on revenue of $33.55 million. The company also raised its 2026 revenue guidance, strengthening the growth outlook. Alamar Q3 results and guidance
• Positive Sentiment: A scientific collaboration with GSK will use Alamar’s NULISA platform to study protein signatures across multiple disease areas. The partnership could increase visibility and validation of the technology, though no financial terms were disclosed. GSK collaboration announcement
• Positive Sentiment: Alamar and Nightingale Health will lead an 80,000-sample UK Biobank study of neurodegenerative disease. The large research project could showcase Alamar’s platform, although its direct commercial impact is not specified. UK Biobank study announcement
• Negative Sentiment: Major shareholder Corporate Gp Vi Ltd. Qiming has continued selling shares, including 43,930 shares on Nov. 2 and 143,706 on Oct. 30, alongside additional sales in October. The transactions may weigh on sentiment; no reason for the sales was disclosed. SEC filing on shareholder sales

Alamar Biosciences Price Performance

The company has a market cap of $1.80 billion and a PE ratio of -13.23. The company has a fifty day moving average price of $30.49. The company has a quick ratio of 10.23, a current ratio of 11.85 and a debt-to-equity ratio of 0.03.

Alamar Biosciences (NASDAQ:ALMR - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.03. The company had revenue of $33.55 million for the quarter. On average, sell-side analysts expect that Alamar Biosciences, Inc. will post -1.22 earnings per share for the current year.

Institutional Trading of Alamar Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. Braidwell LP purchased a new stake in shares of Alamar Biosciences in the second quarter valued at approximately $29,365,000. Wellington Management Group LLP purchased a new position in Alamar Biosciences during the 2nd quarter worth $12,407,000. State Street Corp purchased a new position in Alamar Biosciences during the 2nd quarter worth $3,930,000. Sumitomo Mitsui Trust Group Inc. increased its holdings in Alamar Biosciences by 18.5% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company's stock worth $2,280,000 after purchasing an additional 10,461 shares during the period. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Alamar Biosciences during the 3rd quarter valued at $196,000.

Alamar Biosciences Company Profile

Alamar Biosciences, Inc NASDAQ: ALMR is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.